Stock Events

Stock Events

Ascendis Pharma A/S 

€206
0
+€2+0.98% Thursday 19:55

Statistics

Day High
206
Day Low
202
52W High
210
52W Low
126
Volume
94
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q4 2025
Q1 2026
Next
-0.54
2.84
6.22
9.61
Expected EPS
1.2012478911299342
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow A71.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.77B
Pfizer competes in various therapeutic areas including those targeted by Ascendis Pharma's endocrinology and oncology pipeline.
Novo Nordisk
NVO
Mkt Cap194.57B
Novo Nordisk is a leader in diabetes and growth disorders, directly competing with Ascendis Pharma's growth hormone deficiency treatments.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly has a strong presence in endocrinology, particularly in growth hormone and diabetes treatments, competing with Ascendis' portfolio.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals competes in the development of treatments for genetic disorders, a key area of focus for Ascendis Pharma.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical focuses on rare diseases, including areas like growth disorders, directly competing with Ascendis' therapies.
Opko Health
OPK
Mkt Cap830.6M
OPKO Health has a division focused on pharmaceuticals, including growth hormone treatments, making it a direct competitor.
Ligand Pharmaceuticals
LGND
Mkt Cap2.77B
Ligand Pharmaceuticals' technology platforms and partnerships enable it to compete in the development of endocrinology and oncology drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals competes in the biopharmaceutical space with a focus on innovative treatments, overlapping with Ascendis' therapeutic areas.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on neurological and neurodegenerative diseases but its expansion into other biopharmaceutical areas can position it as a competitor.
AMGEN
AMGN
Mkt Cap178B
Amgen's broad focus on biotechnology treatments for various diseases, including bone health and oncology, places it in competition with Ascendis Pharma.

About

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Show more...
CEO
ISIN
US04351P1012

Listings

STU
DE
A710.STU
STU
DE
A71.STU
MU
DE
A710.MU
MU
DE
A71.MU

0 Comments

Share your thoughts

FAQ

What is Ascendis Pharma A/S stock price today?▼
The current price of A71.STU is €206 EUR — it has increased by +0.98% in the past 24 hours. Watch Ascendis Pharma A/S stock price performance more closely on the chart.
What is Ascendis Pharma A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ascendis Pharma A/S stocks are traded under the ticker A71.STU.
Is Ascendis Pharma A/S stock price growing?▼
A71.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Ascendis Pharma A/S has showed a +52.59% increase.
When is the next Ascendis Pharma A/S earnings date?▼
Ascendis Pharma A/S is going to release the next earnings report on August 06, 2026.
What were Ascendis Pharma A/S earnings last quarter?▼
A71.STU earnings for the last quarter are 9.61 EUR per share, whereas the estimation was 0.16 EUR resulting in a +5,909.21% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Ascendis Pharma A/S located?▼
Ascendis Pharma A/S operates in the Other sector.
When did Ascendis Pharma A/S complete a stock split?▼
Ascendis Pharma A/S has not had any recent stock splits.